The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis - Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M; Fensome, Andrew; Vincent, Michael; Dowty, Martin E; Goteti, Kosalaram; Winkle, Peter J; Peeva, Elena (Journal of clinical pharmacology, 2018)
Keywords: Adolescent; Adult; Aged; Biological Availability; Blood Cell Count; C-Reactive Protein - analysis; Double-Blind Method; Female; Healthy Volunteers; Humans; Janus Kinase 1 - antagonists & inhibitors; Male; Middle Aged; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - blood; Protein Kinase Inhibitors - pharmacokinetics; Psoriasis - blood; Psoriasis - drug therapy; TYK2 Kinase - antagonists & inhibitors; Young Adult; plaque psoriasis; pharmacokinetics and drug metabolism; tyrosine kinase 2 (TYK2); Janus kinase 1 (JAK1) inhibitor; inflammation